Evidence map›Paper›PMID 35805716›Full record

ReviewInternational journal of environmental research and public health2022

The Potential of Thyroid Hormone Therapy in Severe COVID-19: Rationale and Preliminary Evidence.

Iordanis Mourouzis, Vassiliki Apostolaki, Athanasios Trikas, Leonidas Kokkinos, Natassa Alexandrou, Maria Avdikou, Myrto Giannoulopoulou, Aimilia Vassi, Ioulia Tseti, Constantinos Pantos

Registry-linked trialOpen access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of environmental research and public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04348513 (Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04348513 phase2terminatednot on this map

Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection (Thy-Support)

TypeinterventionalSponsorUni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.Ran2020 to 2021Enrolled5ConditionsPulmonary Infection, Covid-19ArmsT3 solution for injection, Placebo
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Endocrine Aspects of ICU-Hospitalized COVID-19 Patients.Journal of personalized medicine · 2022
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Iordanis MourouzisDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Ave., Goudi, 11527 Athens, Greece.
Vassiliki ApostolakiDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Ave., Goudi, 11527 Athens, Greece.
Athanasios TrikasDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Ave., Goudi, 11527 Athens, Greece.
Leonidas KokkinosDepartment of Anesthesiology, ELPIS General Hospital of Athens, 11522 Athens, Greece.ORCID 0000-0003-3010-0208
Natassa AlexandrouDepartment of Anesthesiology, ELPIS General Hospital of Athens, 11522 Athens, Greece.
Maria AvdikouDepartment of Anesthesiology, ELPIS General Hospital of Athens, 11522 Athens, Greece.
Myrto GiannoulopoulouDepartment of Anesthesiology, ELPIS General Hospital of Athens, 11522 Athens, Greece.
Aimilia VassiDepartment of Anesthesiology, ELPIS General Hospital of Athens, 11522 Athens, Greece.
Ioulia TsetiDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Ave., Goudi, 11527 Athens, Greece.
Constantinos PantosDepartment of Pharmacology, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias Ave., Goudi, 11527 Athens, Greece.
General Hospital of Athens Elpis · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tissue hypoxia is one of the main pathophysiologic mechanisms in sepsis and particularly in COVID-19. Microvascular dysfunction, endothelialitis and alterations in red blood cell hemorheology are all implicated in severe COVID-19 hypoxia and multiorgan dysfunction. Tissue hypoxia results in tissue injury and remodeling with re-emergence of fetal programming via hypoxia-inducible factor-1α (HIF-1a)-dependent and -independent pathways. In this context, thyroid hormone (TH), a critical regulator of organ maturation, may be of relevance in preventing fetal-like hypoxia-induced remodeling in COVID-19 sepsis. Acute triiodothyronine (T3) treatment can prevent cardiac remodeling and improve recovery of function in clinical settings of hypoxic injury as acute myocardial infarction and by-pass cardiac surgery. Furthermore, T3 administration prevents tissue hypoxia in experimental sepsis. On the basis of this evidence, the use of T3 treatment was proposed for ICU (Intensive Care Unit) COVID-19 patients (Thy-Support, NCT04348513). The rationale for T3 therapy in severe COVID-19 and preliminary experimental and clinical evidence are discussed in this review.

Indexed as

COVID-19 Drug TreatmentSepsisHumansHypoxiaThyroid HormonesTriiodothyronineThyroid HormonesTriiodothyronineCOVID-19erythrocytehypoxiaright ventriclesepsisthyroid hormone

Identifiers

PMID35805716
PMCPMC9265958
OpenAlexW4283745508

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.